Richard,
You asked a very important question. The numbers just do not add up. The release said the prostate cancer patient's PSA level did not increase from the second month of the initial 3 month period through two months of the follow-up study. Yet the follow-up study lasted 5 months. What happened after the second month of the follow-up study? Did this patient leave the study? Did his PSA level go up?
The way I count it, the release only discussed what happened to 5 patients, not 9 as was mentioned in the first paragraph. It looks like we can only be sure that PN 27,1 has helped 3 patients. It may have helped more patients, but the release is so poorly written it is hard to say. I don't know how much confidence we can put in a drug (supplement) that has only helped 3 patients. The sample size is not large.
And speaking of sample size, the press release at the end of May stated they were trying to find 300 patients for the followup study. What happened? Where did they all go?
I think questions such as these might be keeping the stock price down. The press release, as usual, was as clear as mud. Furthermore, there was some dynamite news buried in the last sentence. The last paragraph of Paracelsian's press release has always been a boilerplate paragraph explaining that Paracelsian is a biotech company blah blah blah. They almost always use the same words to describe what they do. I therefor usually don't read more than the first few words of the last paragraph and skip the rest. If Rick C. had not pointed out the significance of the last sentence, I would not evem have read it. I bet a lot of other people skipped over that part too. I think they should have issued an entire press release announcing that their products would be hitting the market in March and July. They might have made mention of how they planned to distibute it, who it was designed to help, and how large a market they invisioned. Perhaps it is premature to make such a release because they don't have all that information available. They also might want to wait until they have more test results before sticking their necks out so far in such a release. But I don't think people will recognize the significance of this stock until such a release is made public.
Robin Messing |
